direct-to-consumer biohacking

direct-to-consumer biohacking

Growth Hacking vs Smart Pill Who Wins by 2034?

By 2034, growth-hacking-driven smart-pill startups are projected to claim 12% of the global biohacking market, outpacing traditional pharma and securing the larger share of growth. This advantage stems from rapid iteration, data-rich user feedback, and low-cost acquisition tactics that accelerate adoption before regulations settle. Medical Disclaimer: This article is for